Retour

SANOFI-AVENTIS (EPA:SAN) Availability of the Q2 2022 Memorandum for modelling purposes

Directive transparence : information réglementée

24/06/2022 07:32

28/06/2022 07:30

Press Release: Xenpozyme® (olipudase alfa) approved by European...

28/06/2022 07:30

Press Release: Nexviadyme® (avalglucosidase alfa) approved by European...

27/06/2022 22:57

Sanofi: Information concerning the total number of voting rights and...

24/06/2022 07:32

Availability of the Q2 2022 Memorandum for modelling purposes

08/06/2022 11:21

Sanofi launches its first Digital Accelerator fueled by new talent and...

07/06/2022 22:45

Press Release: FDA approves Dupixent® (dupilumab) as first biologic...

02/06/2022 13:30

Press Release: Sanofi grants Regeneron worldwide exclusive license rights...

20/05/2022 21:15

Press Release: FDA approves Dupixent® (dupilumab) as first treatment for...

15/05/2022 09:30

Press Release: Sarclisa® (isatuximab) combination provides unprecedented...

11/05/2022 08:00

Press Release: New nirsevimab data analyses reinforce efficacy against RSV

Voir tous les communiqués de SANOFI-AVENTIS